Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0202


Inhibiting mTOR and VEGF signaling in pancreatic neuroendocrine tumors

Christos S. Katsios, MD.

Affiliation: Christos Katsios, Associate Professor of Surgery, Department of Surgery, University Hospital of Ioannina, Ioannina, TK 45110, Greece.

Tel: +2651099696


Signal transduction drugs, called also targeted agents, have arose great expectations for improving oncological outcomes of patients with solid tumors over the last decade. However, for most targeted drugs developed, with a few exceptions such as trastuzumab or more recently vemurafenib (PLX4032), no overall survival benefit could be obtained. Everolimus and sunitinib have provided substantial antitumor activity in pre-clinical and small clinical studies in the treatment of patients with metastatic pancreatic neuroendocrine tumors. Here I discuss the results of phase 3 randomized clinical trials and their impact on routine clinical practice.

(Citation: Gastric & Breast Cancer 2012; 11(1): 13-19 Rolex Replica Watches)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 30 December 2011